Bimosiamose, discovered by Encysive Pharmaceutical and presently being developed by Revotar Biopharmaceuticals, is an 863 g/mol molecular weight dimer with minimal carbohydrate content and is, to date, the leading selectin inhibitor in clinical development. It was developed as anti-inflammatory drug fir the treatment of acute chronic inflammatory disorders including COPD. This compound has shown promise in a phase IIa 'proof of concept' trial in patients with asthma, reducing airway recruitment of eosinophils after intravenous administration. In acute lung injury, neutrophils (a type of white blood cells, thus belonging to the group of cells of the body’s defence system-the immune system) are drawn to the small lung bloodvessels and migrate into the air sacs (alveoli). There they release substances, which cause the inflammation leading to further destruction of the lung tissue. Bimosiamose disodium is expected to hinder the migration of these neutrophils into the alveoli.

Betacetylmethadol is a synthetic narcotic analgesic under international control according to the UN Single Convention 1961.

Ciproquazone (SL-573) is a non-steroidal anti-inflammatory drug, a derivative of quinazolinone, discovered by Sumimoto Chemical Co. in the late 1970s. Ciproquazone acts as a reversible inhibitor of prostaglandin synthetase. In animal models, ciproquazone demonstrated antipyretic, analgesic and anti-inflammatory activity. The drug was evaluated in a clinical in acute purulent diseases in the field of orodental surgery.

Efipladib is an inhibitor of cytosolic phospholipase A2 alpha both in vitro and in vivo. It is able to relieve inflammatory pain in animal model. Additionally, efipladib exerts antitumor potential. Efipladib was in clinical trials for the treatment of asthma and arthritis however its development has been discontinued.

Fluprofen was invented as an analgesic and anti-inflammatory agent. However, information about the current use of this drug is not available.

Pipequaline (PK-8165, 2-phenyl-4[2-(4-piperidinyl) ethyl]quinoline) is a benzodiazepine receptor partial agonist.

Sufosfamide is an oxazaphosphorine derivative patented by Asta-Werke A.-G as immunosuppressives agent. Sufosfamide is a mixed-function oxazaphosphorine differing from ifosfamide in that the extracyclic 2-chloroethyl function has been replaced by a mesyl-oxyethyl group. It is characterized by an extraordinary intensifi¬cation of the immunosuppressive component of action compared to the carcinotoxic component. Sufosfamide activates of a specific immune tolerance in models of humoral end cell-bound antibodies.

Prenoverine is diphenylmethanol derivative patented by Andreu, Dr. S. A. as a muscle relaxant. Prenoverine shows good multidrug resistance-reversal activity.

Camiverine is phenylacetate derivative with cardio-vascular. Its antispasmodic action was 1/16 that of atropine (for the acetylcholine spasm) and 6.7-19.4 times that of papaverine for the BaCl2 and the histamine spasm, both tests in vitro. No chronic toxicity was observed for the oral dose of 50-100 mg/kg daily for 60 days in rats.

Trecadrine is a beta3-adrenergic agonist. Trecadrine could have normalized the oxygen consumption by the liver, in which other metabolic pathways could be involved. The administration of Trecadrine produced a statistically significant decrease in glucose levels, which is not related to changes in insulin levels. Trecadrine administration to animals significantly inhibited galactose intestinal absorption, which was independently confirmed by additional in-vitro studies and decreased disaccharidase activities. Trecadrine enhance glucose storage in liver, probably through a non-insulin dependent mechanism of action. Trecadrine administration may have a therapeutic potential in disorders associated with hypertriglyceridemia such as obesity and some types of hyperlipidaemias. Trecadrine shows a potent hypoglycaemic effect in the alloxan-induced model of diabetes in rats by decreasing hepatic glucose output and improving muscle glucose uptake.